Pacific Edge
on its
NZ$21m
equity
capital raising
- Cameron Partners advised NZX/ASX listed Pacific Edge in relation to its NZ$21m capital raising via a placement and retail SPP offer
- The placement was undertaken at a premium and was oversubscribed and upsized to NZ$16m following strong support from New Zealand institutional investors. The NZ$5m retail SPP also received strong shareholder support
- Pacific Edge develops and commercialises a suite of pioneering non-invasive genomic bladder cancer diagnostic tests (Cxbladder) for patients in the US, New Zealand and other global markets
